NEW YORK The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.
David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.
Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.
Trending On Reuters
British lawmakers urged the government to introduce tough measures, including a tax on sugary drinks and controls on price promotions for "unhealthy food and drink", to help tackle childhood obesity. Full Article